Form 8-K VERU INC. For: Jun 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall St futures rise on Mideast deal optimism; SpaceX debut in focus
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Oil falls to near two-month lows as Trump calls off threatened strikes on Iran
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Wall St set to gain on tech rebound, Middle East in focus
Veru partners with Novo Nordisk for obesity drug combination study
June 4, 2026 8:42 AM EDTVeru Inc. (NASDAQ: VERU) entered into a clinical supply agreement with Novo Nordisk A/S on June 2, 2026, for the company's Phase 2b PLATEAU clinical study.
The study will evaluate the combination of Veru's enobosarm, an oral selective androgen receptor modulator, with Novo Nordisk's... More
